The Latest Cardiac and Vascular News
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, has announced the first patient enrollment in the Perceval® Valve Clinical study for Chinese Registration (“PERFECT”) Trial. The study is a pre-market, prospective, single-arm trial. The PERFECT trial […]
LONDON–(BUSINESS WIRE)– LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) today announced that it has entered into a definitive Stock and Asset Purchase Agreement (“Purchase Agreement”) to divest its Cardiac Rhythm Management business franchise to MicroPort Scientific Corporation (“MicroPort”). LivaNova and MicroPort executed and delivered the Purchase Agreement, […]
LivaNova to Acquire TandemLife Company will add advanced cardiopulmonary temporary support solutions to its portfolio LONDON–(BUSINESS WIRE)– LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it has entered into an agreement to acquire TandemLife, a privately held […]
Company celebrates new design that delivers improved flexibility, clarity and control LONDON–(BUSINESS WIRE)– LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced it has achieved CE Mark for its new PureFlexTM line of adult arterial cannulae. Engineered to […]
LONDON–(BUSINESS WIRE)– LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced that the first patient has been enrolled in the Behavior of Valve Leaflets and the Incidence of Reduced Mobility Post-Surgical Aortic ValveImplant Study (“BELIEVE”). This study is a post-market, […]
LONDON & SHANGHAI–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) and MicroPort Scientific Corporation (HK:00853) (“MicroPort”) today announced that the companies have entered into a binding Letter of Intent (“LOI”) for the sale of LivaNova’s Cardiac Rhythm Management (“CRM”) Business Franchise to MicroPort […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) and MicroPort Scientific Corporation (HK:00853) (“MicroPort”), today announced that the companies’ Shanghai-based joint venture MicroPort Sorin Cardiac Rhythm Management Co. Ltd. (“MSC” or the “joint venture”) obtained approval for its family of RegaTM pacemakers from the […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, hosted its Investor Day today in New York to showcase the Company’s strategy, business goals and financial outlook. LivaNova’s Chief Executive Officer Damien McDonald shared his strategic […]
September 14, 2017: LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today announced it is exploring strategic options for its Cardiac Rhythm Management (“CRM”) Business Franchise. “As part of our ongoing efforts to […]
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN) (“LivaNova” or the “Company”), a market-leading medical technology company, today announced the publication of the analysis, “The Perceval® Sutureless Aortic Valve: Review of Outcomes, Complications and Future Direction,” by Powell, Pelletier, Chu, Bouchard, Melvin and Adams in […]
